EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Body mass index as a predictive factor for efficacy of adjuvant taxane‐based chemotherapy in early‐stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

José A García-Saenz iD, Gonzalo Spera, Marina Pollán, Begoña Bermejo, Manuel Ruiz-Borrego, Arlene Chan iD, Miguel Martín, Ángel Guerrero-Zotano, Lourdes Calvo, Álvaro Rodríguez-Lescure, María Marín, Linnea Chap und 7 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von José A García-Saenz und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Body Mass Index, Taxoids, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adjuvant anthracyclines and taxanes reduce recurrence and death in early‐stage breast cancer (EBC) patients, but toxicity is a concern. Studies show conflicting results on the correlation between body mass index (BMI) and outcomes. Limited data exist on the efficacy of adjuvant taxanes among BMI categories and the impact of different taxane‐based chemotherapies (paclitaxel vs. docetaxel) on disease recurrence. Here, we present a pooled analysis of 13,486 EBC patients treated with adjuvant anthracyclines ± taxanes from seven GEICAM and TRIO trials (1996–2008) conducted. Patients were classified into four BMI categories: normal (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBody Mass IndexTaxoidsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedChemotherapy, AdjuvantAdultAgedDocetaxelNeoplasm StagingObesityPaclitaxelPrognosisAnthracyclinesTreatment Outcome

Stichwörter der Autor:innen

body mass indexdocetaxelearly‐stage breast cancerpaclitaxelpooled analysissurvival

Substanzen

TaxoidsDocetaxelPaclitaxelAnthracyclines

Autor:innen und Institutionen

  • Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain.
  • GEICAM, Spanish Breast Cancer Group, Madrid, Spain.
  • Translational Research in Oncology, Medical Affairs, Montevideo, Uruguay.
  • Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
  • Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
  • Hospital Clínico Universitario de Valencia, INCLIVA Instituto de Investigación Sanitaria, Universidad de Medicina de Valencia, Valencia, Spain.

ORCID-Profile: José A García-Saenz, Arlene Chan

Zitieren

APA

García-Saenz, J. A., Spera, G., Pollán, M., Bermejo, B., Ruiz-Borrego, M., Chan, A., Martín, M., Guerrero-Zotano, Á., Calvo, L., Rodríguez-Lescure, Á., Marín, M., Chap, L., Crown, J., Pienkowski, T., Bee, V., Casas, M., Polonio, Ó., Bezares, S., & Slamon, D. (2025). Body mass index as a predictive factor for efficacy of adjuvant taxane‐based chemotherapy in early‐stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies. International Journal of Cancer. https://doi.org/10.1002/ijc.35432

Vancouver

García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, et al. Body mass index as a predictive factor for efficacy of adjuvant taxane‐based chemotherapy in early‐stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies. International Journal of Cancer. 2025. doi:10.1002/ijc.35432

BibTeX
@article{GarcaSaenz2025,
  author = {García-Saenz, José A and Spera, Gonzalo and Pollán, Marina and Bermejo, Begoña and Ruiz-Borrego, Manuel and Chan, Arlene and Martín, Miguel and Guerrero-Zotano, Ángel and Calvo, Lourdes and Rodríguez-Lescure, Álvaro and Marín, María and Chap, Linnea and Crown, John and Pienkowski, Tadeusz and Bee, Valerie and Casas, Maribel and Polonio, Óscar and Bezares, Susana and Slamon, Dennis},
  title = {Body mass index as a predictive factor for efficacy of adjuvant taxane‐based chemotherapy in early‐stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35432}
}
Kostenlos starten →